GlassScriptPhysician profile
Sherelene Fortney
NPI 1578549036
$2,526.17
in general payments reported to CMS, 2019-2025
27 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $687 · 2022: $118 · 2023: $508 · 2024: $680 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $410.48 | 2023-2025 | |
| Novo Nordisk INC | $221.49 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $188.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $188.54 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $169.56 | 2022-2025 | Farxiga, Tezspire, Breztri |
| Lilly USA, LLC | $165.97 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $136.80 | 2021-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $122.40 | 2021 | |
| Insulet Corporation | $120.72 | 2021-2023 | Omnipod |
| Medtronic, INC. | $101.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $97.12 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $90.43 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $75.40 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $54.67 | 2021-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $50.76 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $49.39 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.99 | 2024-2025 | Caplyta |
| Dexcom, INC. | $39.72 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $34.25 | 2023-2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $31.03 | 2023-2025 | Abilify Maintena, Nuedexta |
| Upsher-Smith Laboratories LLC | $27.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.49 | 2021 | |
| Amgen INC. | $18.16 | 2024 | Repatha, Otezla |
| Axsome Therapeutics, INC. | $17.30 | 2024 | Auvelity |
| Ars Pharmaceuticals Operations, INC. | $14.74 | 2025 | Neffy |
| Amarin Pharma, INC. | $14.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherelene Fortney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.